Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS Framework Agreement for Adalimumab Injection
Offer reference number: CM/PHR/19/5575
Period of Framework Agreement:
1 April 2020 - 31 March 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| AbbVie Ltd | 08004972 | ~£445,000,000 estimated from lot values | LOBBYIST Policy Connect Limited (15 quarters) Portland PR Limited (3 quarters) WA Communications Ltd (3 quarters) Incisive Health Ltd (1 quarter) Political Lobbying & Media Relations Limited (1 quarter) |
| Amgen Ltd. | 02354269 | ~£445,000,000 estimated from lot values | - |
| Biogen Ltd. | 06151086 | ~£445,000,000 estimated from lot values | - |
| Fresenius Kabi Limited | 02182135 | ~£445,000,000 estimated from lot values | - |
Government spending data: These suppliers have received £79,423,549 in 3,716 payments (over £25k) from NHS Supply Chain (DHSC-funded), Guy's and St Thomas' NHS FT, Department of Health and Social Care, University Hospitals Bristol and Weston NHS FT, Manchester University NHS Foundation Trust and 10 more public bodies (2019-04-17 to 2026-03-31).